Neurodevelopmental defects of the thalamocortical pathway as a convergent feature of psychiatric disorders

PROJECT SUMMARY Brain function emerges from the activity of hundreds of neuronal types embedded within a complex network of neural circuits. Although the formation of neural circuits is guided by the emergent activity, many of the initial ‘wiring instructions’ are genetically encoded. Mutations in genes associated with neurodevelopmental psychiatric disorders may disrupt the early stages of cell type and circuit development, leading to long-lasting deficits in function. Our overarching goal is to identify the molecular and cellular mechanisms that govern neuronal cell type specification and their early connectivity preferences. Disease associated mutations serve as a discovery platform of molecular mechanisms that likely disrupt connectivity. In this project, we focus on the development of the human thalamus and early stages of thalamocortical pathway formation. Given the central role of the thalamocortical pathway in sensory, motor, and cognitive tasks, understanding its development in the human brain would be fundamental to studies modeling the consequences of mutations associated with multiple neuropsychiatric symptoms. Remarkable differences between mouse and human development of the thalamocortical pathway pose a scientific challenge for studying the impact of genetic variants on human thalamocortical pathway development, especially during its early formation. Innovations of in vitro differentiation protocols for induced pluripotent stem cells have recently enabled studies of early formation of the human thalamocortical pathway using organoids. As an exemplar, we propose to investigate thalamocortical and corticothalamic axon outgrowth in organoids derived from patients with 22q11.2 microdeletion syndrome, which is associated with schizophrenia, autism, movement disorders, developmental delays, and epilepsies. Neuroimaging studies in 22Q11 Deletion Syndrome (22Q11DS) patients have identified differences in functional thalamocortical connectivity between patients and healthy control, establishing a scientific premise for examining thalamocortical pathway development in cells with 22q11.2 microdeletion. Investigations of neurodevelopmental defects using stem cell models will be complemented by a parallel effort using a mouse model of human 22q11.2 microdeletion. We will identify molecular changes in cell fate specification of thalamic neurons, and compare axonal outgrowth phenotypes in control and cells with the 22q11.2 microdeletion. Our preliminary data implicate FOXP2 transcription factor activity in mediating thalamocortical pathway growth phenotypes in 22q11.2 DS thalamic neurons. The proposed project will establish groundwork for studying the growing list of rare genetic mutations with high effect size discovered through large scale studies of Autism, ADHD, and schizophrenia patients for their role in brain development, focusing on the development of the thalamocortical pathway.